ROCHE HOLDING AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 220.8 CHF | +0.34% |
|
-2.65% | -9.98% |
| Apr. 17 | Roche’s Multiple Sclerosis Injection Controls Relapses, Brain Lesions in Late-stage Trial | MT |
| Apr. 17 | Roche: positive phase III results in MS | CF |
| Sales 2024 * | 59.84B 65.79B | Sales 2025 * | 63.41B 69.71B | Capitalization | 177B 195B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.38B 14.71B | Net income 2025 * | 14.66B 16.11B | EV / Sales 2024 * | 3.19 x |
| Net Debt 2024 * | 13.47B 14.81B | Net Debt 2025 * | 7.31B 8.03B | EV / Sales 2025 * | 2.91 x |
| P/E ratio 2024 * |
13.2
x | P/E ratio 2025 * |
11.9
x | Employees | 103,605 |
| Yield 2024 * |
4.36% | Yield 2025 * |
4.53% | Free-Float | 88.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding AG
More recommendations
More press releases
More news
| 1 day | -0.41% | ||
| 1 week | -1.92% | ||
| Current month | -4.18% | ||
| 1 month | -4.64% | ||
| 3 months | -10.98% | ||
| 6 months | -12.83% | ||
| Current year | -9.98% |
1 week
218.70
227.20
1 month
217.00232.00
Current year
217.00255.90
1 year
217.00293.55
3 years
217.00404.20
5 years
217.00404.20
10 years
206.35404.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 65 | 95-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.03% | 121 M€ | -.--% | - | |
| 8.46% | 18 M€ | +2.91% | - | |
| 4.67% | 2 M€ | -.--% | ||
| 2.85% | 6 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 220.3 | +0.09% | 57 530 |
| 24-04-17 | 220.1 | -0.63% | 1,102,421 |
| 24-04-16 | 221.5 | -1.60% | 1,195,512 |
| 24-04-15 | 225.1 | +0.04% | 761,091 |
| 24-04-12 | 225 | -0.49% | 1,292,148 |
Delayed Quote Swiss Exchange, April 17, 2024 at 11:31 am EDT
More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q1 2024 Sales and Revenue Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
220.1
CHF
Average target price
281.6
CHF
Spread / Average Target
+27.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.98% | 194B | |
| +28.79% | 676B | |
| +24.81% | 554B | |
| -7.64% | 349B | |
| +15.00% | 318B | |
| +5.99% | 291B | |
| +2.47% | 210B | |
| -0.02% | 204B | |
| -11.71% | 144B | |
| -8.32% | 142B |
- Stock Market
- Equities
- ROG Stock
